(NASDAQ: ORKA) Oruka Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Oruka Therapeutics's earnings in 2026 is -$116,254,000.On average, 14 Wall Street analysts forecast ORKA's earnings for 2026 to be -$138,295,648, with the lowest ORKA earnings forecast at -$165,496,405, and the highest ORKA earnings forecast at -$115,636,391. On average, 14 Wall Street analysts forecast ORKA's earnings for 2027 to be -$163,041,703, with the lowest ORKA earnings forecast at -$216,918,502, and the highest ORKA earnings forecast at -$86,758,957.
In 2028, ORKA is forecast to generate -$191,322,047 in earnings, with the lowest earnings forecast at -$317,398,463 and the highest earnings forecast at -$127,921,966.